Company intelligence / Profile preview
Bolt Biotherapeutics
Redwood City, California, United Statesboltbio.com ↗
- Ownership
- Public · BOLT
- Employees
- ~52
- Development stage
- Other
01
Overview
BDC-3042 Phase 1 trial showed the drug was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events. It demonstrated biological activity with dose-dependent increases in proinflammatory cytokines and showed signs of anti-tumor activity, including an unconfirmed partial response and stable disease ≥12 weeks in 3/3 non-small cell lung cancer patients.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesImmune-Stimulating Antibody Conjugates (ISACs)Agonist antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Genmab A/SToray IndustriesInnovent Biologics, Inc.
04
Financials
- Market cap
- $12.3M
- Total revenue
- $7.7M
- Enterprise value
- $16.3M
Beyond the preview
Go deeper on Bolt Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bolt Biotherapeutics.